CYP2W1 and neoplasm: In preclinical studies, CYP2W1 demonstrates the ability to selectively bioactivate prodrugs, such as duocarmycin analogs and AQ4N, into highly cytotoxic metabolites within tumor cells [15,16,17], thereby minimizing damage to normal tissues.